Please assess the completion status of the following clinical trial:

Trial Title: Trial of Percutaneous Tibial Nerve Stimulation (PTNS) Versus PTNS and Fesoterodine Fumarate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female ages \> 18 and \< 100 years old without childbearing potential~* History of overactive bladder~  * with or without urge incontinence)~ * with or without a history of previous anticholinergic use~* At least 8 voids per 24 hours documented by history and physical and voiding diary~Exclusion Criteria:~* Has had PTNS modulation in the past~* Has a primary complaint of stress urinary incontinence~* History of an allergy or sensitivity to tolterodine tartrate tablets or its ingredients~* History of an allergy or sensitivity to fesoterodine tartrate tablets or its ingredients~* Has a recent positive urinalysis for infection~* Has taken anticholinergic medication in the last 4 weeks for overactive bladder~* Has any of the following:~  * pacemakers or implantable defibrillators~ * excessive bleeding~ * urinary or gastric retention~ * nerve damage and/or neuropathy~ * myasthenia gravis, uncontrolled narrow angle glaucoma~ * liver disease or kidney disease~ * QT prolongation.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PTNS + fesoterodine fumarate first, then PTNS + placebo (Type: ACTIVE_COMPARATOR): Participants were to be given Percutaneous Tibial Nerve Stimulation (PTNS) + 4mg of fesoterodine fumarate first for 12 weeks, and followed by 4 weeks of washout followed by 12 weeks of PTNS + placebo.
- PTNS + placebo first, then PTNS + fesoterodine fumarate (Type: PLACEBO_COMPARATOR): Participants were to be given Percutaneous Tibial Nerve Stimulation (PTNS) + placebo for 12 weeks followed by 4 weeks of washout followed by 12 weeks of PTNS + 4mg of fesoterodine fumarate

Based on this trial design, predict the completion outcome and termination type (if applicable).